Cymab ApS
CVR 39859173 · Private limited company (ApS) · Active · Low risk
Cymab ApS is a Private limited company (ApS), founded on , based in København N. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 0.5% over the next 12 months, which is 0.4 times the average for Danish companies. 7 annual reports have been published, of which 1 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK -20.2m and a net result of DKK -7.6m.
Bankruptcy risk for Cymab ApS
0.4 × the average (1.41%) · higher risk than 60% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 39859173
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (8 years)
- Address
- Ole Maaløes Vej 3
2200 København N - Municipality
- København
- Industry
- Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater - Share capital
- DKK 50k
- Auditor
- Beierholm Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 1 of 7 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -350.0% |
| Current ratio | 225% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 7 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 167 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | DKK -5.5m | DKK -2.0m | DKK -1.2m |
| Net profit | DKK -7.6m | DKK -4.6m | DKK -2.6m |
| Equity | DKK -20.2m | DKK -12.7m | DKK -8.0m |
| Total assets | DKK 5.8m | DKK 12.6m | DKK 5.6m |
| Cash | DKK 1.5m | DKK 8.5m | – |
| Short-term debt | DKK 2.6m | DKK 2.0m | – |
| Avg. employees | 3 | 3 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · Beierholm.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 176 | ||
| 1 Jan 2024 – 31 Dec 2024 | 167 | ||
| 1 Jan 2023 – 31 Dec 2023 | 181 | ||
| 1 Jan 2022 – 31 Dec 2022 | 181 | ||
| 1 Jan 2021 – 31 Dec 2021 | 172 | ||
| 1 Jan 2020 – 31 Dec 2020 | 162 | ||
| 10 Sep 2018 – 31 Dec 2019 | 227 | Late |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Kurt Flemming Holmsted | ||
| CEO | Johan Henrik Faber | ||
| CEO | Stine Louise Reedtz Kjellev | ||
| CEO | Anne Reker Cordt | ||
| Board | Johan Henrik Faber | Current | |
| Board | Søren Erik Bjørn | Current | |
| Board | Hans Heugh Wandall | Current | |
| Board | Thomas Dal Stenfeldt Batchelor | Current | |
| Board | Mads Nikolaj Behrndt-Eriksen | Current | |
| Board | Kurt Flemming Holmsted | ||
| Board | Hans Heugh Wandall | ||
| Board | Kim Stengaard Holmsted | ||
| Board | Thomas Dal Stenfeldt Batchelor | ||
| Board | Hans Heugh Wandall | ||
| Board | Hans Heugh Wandall | ||
| Board | Thomas Dal Stenfeldt Batchelor | ||
| Board | Anne Reker Cordt | ||
| Owner (100%) | Ebumab Holding ApS | Current | |
| Auditor | Beierholm Godkendt Revisionspartnerselskab | Current | |
| Auditor | KAPPELSKOV REVISION. GODKENDT REVISIONSAKTIESELSKAB | ||
| Auditor | Slotsgade Revision ApS | ||
| Founder | Ebumab Holding ApS | Current |
The CEOs' other companies
Kurt Flemming Holmsted – 45 other companies, of which 8 bankrupt
- AKTIESELSKABET AF 8. MARTS 2013 Bankrupt 28 Jun 2013
- COPY DATA SERVICES A/S Bankrupt 15 May 2013
- ENIGMA ENGINEERING A/S Bankrupt 8 Nov 2002
- Kifo Sommer ApS (1) Bankrupt 27 Oct 1994
- NELLY AGUSTAR ApS Bankrupt 3 Feb 1992
- SELSKABET AF 5. MARTS 2013 A/S Bankrupt 13 Mar 2013
- SELSKABET AF 7. DECEMBER 1982 A/S Bankrupt 16 May 2013
- SUSAN AGUSTAR A/S Bankrupt 3 Feb 1992
- A. HENRIKSEN SHIPPING A/S Active
- A. HENRIKSEN SHIPPING HOLDING ApS Active
- BANYULS SUR MER ApS Opløst
- DANCENTER A/S Active
- DANCENTER EDB-SERVICE ApS Active
- DANLAND A/S Fusioneret
- DANSK CENTRALKONTOR FOR SOMMERHUS-UDLEJNING ApS Active
- DCSU A/S Active
- DCSU II ApS Opløst
- DCSU II Holding ApS Opløst
- DCSU III Holding ApS Opløst
- DCSU INVEST I A/S Opløst
- DCSU INVEST II ApS Opløst
- DCSU INVEST III ApS Opløst
- ER3 ApS Opløst
- ER4 ApS Active
- EUROMILLING A/S Active
- Ebumab Holding ApS Active
- FIRST LAND A/S Opløst
- FPE ET ApS Active
- FPE ET B ApS Active
- FPE FEM ApS Opløst
Johan Henrik Faber – 4 other companies
- Ebumab Holding ApS Active
- Ebumab Sandbox ApS Active
- Hemab ApS Active
- Johan H. Faber ApS Active
Anne Reker Cordt – 3 other companies
- BIOARC HOLDING APS Active
- GynStudio ApS Active
- p.A.c. ApS Opløst
Address history (1 moves)
| Ole Maaløes Vej 3, 2200 København N | |
| Endrupvej 41, 3480 Fredensborg |
Former names
| Cymab ApS | – now |
| Ebumab ApS | – |
Other companies at the same address
- 25-06-2019 ApS Bankrupt
- Ankrin Therapeutics ApS Bankrupt
- Avineuro ApS Bankrupt
- BIOREPELLER IVS Bankrupt
- Bainan Biotech ApS Bankrupt
- Broselid Holding IVS Bankrupt
- ChildTreat ApS Bankrupt
- Dencomm ApS Bankrupt
- IO BIOTECH ApS Bankrupt
- Invitreo Biosciences ApS Bankrupt
- Lab Hos Development ApS Bankrupt
- MGM BIO IVS Bankrupt
- Mind the Byte ApS Bankrupt
- PanCryos ApS Bankrupt
- Ressaissi Holding IVS Bankrupt
- SSIP 2023 ApS Bankrupt
- Spit Test Company ApS Bankrupt
- Sterisafe Holding A/S Bankrupt
- Sumondo ApS Bankrupt
- TychoBio IVS Bankrupt
- aiwell Nordic ApS Bankrupt
- 1stBiome ApS Active
- 3Sonic ApS Active
- 55 North General Partner I ApS Active
- 55 North Management ApS Active
Similar companies in København
- H. LUNDBECK A/S Valby
- GUNNAR KJEMS ApS København K
- Tetrapharm Therapeutics ApS København S
- Tetrapharm Bioengineering ApS København S
- Luvalis Pharma ApS Vanløse
- NeuroVersis Therapeutics ApS København K
- QuantumCell ApS København K
- Vautia Therapeutics ApS København K
- Corxel Pharmaceuticals Denmark ApS København V
- Dispersome IP ApS København Ø
- Maddox Pharma Swiss ApS København S
- Gefjon Pharma ApS København N
Questions and answers about Cymab ApS
Has Cymab ApS gone bankrupt?
No, Cymab ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Cymab ApS?
Our model estimates a bankruptcy risk of 0.5% over the next 12 months (low risk), which is 0.4 times the average for Danish companies.
Who is the auditor of Cymab ApS?
Cymab ApS most recently used Beierholm Godkendt Revisionspartnerselskab.
When was Cymab ApS founded?
Cymab ApS was founded on 10 September 2018.
What is the equity of Cymab ApS?
Equity was DKK -20.2m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.